BLACK WEEKSHætteglas −15% · kits −10% · resten −5%med kodeGratis fragt i Tyskland fra €200

Denne side er oversat automatisk og kan indeholde fejl. Har du dansk som modersmål? Vi hører meget gerne din feedback og dine rettelser.Send feedback

The Peptide Desk The Peptide Desk
Tamoxifen (Nolvadex), produktfoto

Laboratorierapport

PDF
Testet
Testet
Tamoxifen (Nolvadex) 20mg × 100 Tabs
Laboratorium
Analiza Białek
Dato
October 2026
Resultat
20.34 mg per tablet (20 mg label)
Ordrenr.
Adgangskode

Uafhængigt testet, kan verificeres med adgangskoden direkte hos laboratoriet.

PCT & AI

Tamoxifen (Nolvadex)

PCT & AI

Bestilling

Stykpris - Gratis fragt i Tyskland fra 200 € under Black Weeks
  • DHL med sporing
  • Diskret emballage

4.6 ud af 5 på Trustpilot73 anmeldelser

Kort fortalt

Tamoxifen (Nolvadex) i tal

Nøgletallene fra vores leksikon.

Hele leksikonopslaget
Class
SERMestrogen receptor modulator
Half-life
longseveral days
Use
Oraldaily
Sizes
10 to 20 mg2 sizes in the shop

Viden

Alt om Tamoxifen (Nolvadex)

FAQ

Ofte stillede spørgsmål

Kilder til hvert svar: leksikonopslag

Har du stadig et spørgsmål?

Skriv til os, vores team hjælper dig.

Is tamoxifen approved?

Yes. ChEMBL lists tamoxifen with phase 4 as the highest phase and first approval in 1977. ClinicalTrials.gov lists 685 trials with tamoxifen, almost all on breast cancer, as of 26 October 2026.

How well did tamoxifen prevent gynecomastia in the trial?

114 men received the antiandrogen bicalutamide for 48 weeks, plus placebo, tamoxifen or anastrozole. Gynecomastia developed in 73 percent on placebo, 10 percent on tamoxifen and 51 percent on anastrozole. Breast pain occurred in 39, 6 and 27 percent.

Why was anastrozole weaker?

Anastrozole lowers the production of estrogen, tamoxifen blocks the effect directly at the receptor in the breast gland. In the trial anastrozole did not significantly reduce gynecomastia. A meta-analysis of 9 trials also found no significant benefit for anastrozole.

What does the meta-analysis show?

Nine randomised trials in men on bicalutamide were included. Tamoxifen lowered the risk of gynecomastia and breast pain by 82 percent (relative risk 0.18). Breast radiotherapy lowered the risk of gynecomastia by 52 percent.

Are there data on gynecomastia of unknown cause?

A breast clinic followed 81 men who received tamoxifen over 10 years. In 90.1 percent the gynecomastia resolved completely. There was no control group, so the evidence is limited.

What happened to the hormones?

Testosterone rose in all groups. With tamoxifen free testosterone stayed the same because the binding protein SHBG rose. Adverse events were not more common with tamoxifen than without (35 versus 37 percent).

Sammenligninger

Sådan klarer den sig

Relateret

Relaterede produkter